In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Boon and bane: dodging participant burden in decentralised clinical trials
As DCT adoption increases, Harpreet Gill, Head of Decentralised Clinical Trial Solutions at ICON contributes to this piece in Clinical Trials Arena which looks at how sponsors and CROs must mind the risk of adding patient burden while designing decentralised trials.
Verdict Media Limited 2022
-
The evolving relationship between sponsors and contract research organisations
If the last few years have taught us anything, it’s that so much more can be achieved when all players in the life sciences and pharmaceutical industries work together in a truly collaborative way. The opportunity for the clinical development industry is to take what we have learned about how we can work together and use this to continue to drive progress. To strategically support clients, at ICON, this means partnering with sponsors in a way that goes beyond a traditional CRO. It means being a trusted partner.
In this podcast and article Jeff James, EVP Alliance Management, offers his perspective on what it takes to be a trusted partner to sponsors in the clinical development industry. -
Measuring the cost-effectiveness of vaccines targeting infectious diseases
ICON's Richard Pitman and Pragya Khurana provide insights on the use of real world evidence to build cost-effectiveness models that demonstrate the value that vaccines bring to healthcare systems.
-
Drug development practices to improve public health policy
In this article, Dr Andrew Garrett, Executive Vice President of Scientific Operations, explores the need for interdisciplinary collaboration between pharmaceutical and non-pharmaceutical researchers and public health centres to consider the overlap between NPIs and PIs and identify where standards can be improved and enforced.
-
Responsive strategies in vaccine development
Shelley McLendon discusses the importance of disease surveillance, developments in early outbreak detection, and the role of smart data reporting and adaptive trial designs.
-
Mainstreaming cell and gene therapy – Realizing its potential
This article looks at the Cell and gene therapies (CGT) landscape, the challenges biopharma companies face in running clinical trials and tips on how to surmount those obstacles.
-
Language: A key component of diverse and inclusive trials
What is the role and significance of language and medical translation within clinical trials? ICON Language Services Director Patrick Majewski shares the importance of and key considerations in clinical trial translations.
-
The role of digital health technology tools in supporting medical adherence
In this article in Pharmaceutical Market Europe, Dr Peter Schueler and Dr Isaac R Rodriguez Chavez outline the role of digital health technology tools in supporting medical adherence. 2022 PM Group
-
Voice enabling participant diary collection powered by AI on AWS – Part 2
Together with Amazon Web Services (AWS), the ICON team worked to understand how to develop voice capabilities in the context of an operational plan to establish a framework that can be extended when demand for Voice in clinical research grows.
By understanding how to develop a private AMAZON VOICE SKILL using ALEXA/LEX framework for eCOAs including ePROs, and documenting future integration points with the ICON Digital Platform (IDP), ICON has completed foundational steps in the implementation of voice capabilities.
This blog outlines considerations for integrating voice-enabled diary data within a clinical trial, and serves as an example of how ICON applies innovation to enable efficient and effective patient participation in clinical research.
-
Inclusive approaches to diversity and inclusion
Devra Densmore, Senior Lead of Patient Advocacy Strategy at the Centre for Rare Diseases at ICON, discusses the importance of DEI in rare disease clinical trials and shares actionable points for a more inclusive approach.
